HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
November 14, 2024 16:05 ET
|
HOOKIPA Pharma Inc.
Enrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data...
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
November 11, 2024 16:05 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a clinical-stage biopharmaceutical company developing next generation...
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
October 31, 2024 09:17 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation...
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
October 30, 2024 07:30 ET
|
HOOKIPA Pharma Inc.
Study done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate...
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
September 24, 2024 07:30 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a clinical-stage biopharmaceutical company developing next generation...
HOOKIPA Pharma Announces Board of Directors Changes
August 30, 2024 08:00 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its...
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024 16:30 ET
|
HOOKIPA Pharma Inc.
New Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 “AVALON-1” study with eseba-vec in Q4 2024 ...
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024 08:30 ET
|
HOOKIPA Pharma Inc.
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations...
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 08, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
July 01, 2024 16:31 ET
|
HOOKIPA Pharma Inc.
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency...